MDNA | Medicenna Therapeutics Corp
Quick infos Trade prices Volume: Market Cap: 44.35M Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: No Dividends Next ER: June 22, 2022 Before Market Opens
Company Profile Medicenna is a clinical stage immunotherapy company that engineers novel, powerful and proprietary interleukins we call Superkines. Leveraging our Superkine Platform, we are able to modulate, fine-tune or amplify the immune system to tackle the most challenging diseases, including a broad range of cancers with tremendous unmet need.
Earnings History Date EPS / Forecast Revenue / Forecast August 12, 2022 May 13, 2022 -0.1008 / -0.1053- / -February 9, 2022 -0.09 / -0.1268- / -November 12, 2021 -0.15 / -0.1503- / -August 13, 2021 -0.12 / -0.0925- / -view more
Historical Data Date Price Open High Low Vol Change ER Jun 22, 2022 1.27 1.13 1.31
1.09
82.18K 14.41% Jun 21, 2022 1.11 1.07 1.11
1.03
18.54K 3.74% Jun 20, 2022 1.07 1.08 1.09
1.05
2.79K 3.88% Jun 17, 2022 1.03 1.03 1.03
1.03
1.30K 4.04% Jun 16, 2022 0.99 1.02 1.05
0.98
24.76K -6.6% Jun 15, 2022 1.06 1.05 1.11
1.04
8.42K 3.92% Jun 14, 2022 1.02 1.05 1.08
1.02
18.02K -3.77% Jun 13, 2022 1.06 1.25 1.25
1.04
20.02K -13.11% Jun 10, 2022 1.22 1.12 1.28
1.12
14.89K 7.96% Jun 9, 2022 1.13 1.14 1.16
1.13
6.31K -0.88% view more
More profiles and info about the company News
Medicenna Therapeutics reports FQ2 results seekingalpha.com Nov 12, 2021 8:06 pm Medicenna granted FDA clearance to expand cancer study in U.S. seekingalpha.com Oct 27, 2021 8:31 pm Medicenna adds John Sampson to its board of directors seekingalpha.com Sep 24, 2021 4:38 am Medicenna issued U.S. patent for its MDNA11 program intellectual property seekingalpha.com Sep 20, 2021 8:41 pm Medicenna Therapeutics reports Q1 results seekingalpha.com Aug 13, 2021 7:10 pm Medicenna shares rise on MDNA11 cancer study timeline update seekingalpha.com Jul 27, 2021 9:22 pm Medicenna submits clinical trial application in Australia for a phase 1/2 study of MDNA11 seekingalpha.com Jun 23, 2021 9:46 pm Medicenna Therapeutics reports FY results seekingalpha.com May 28, 2021 7:36 pm Medicenna names immuno-oncology expert Mann Muhsin as chief medical officer seekingalpha.com May 12, 2021 9:27 pm Medicenna posts positive data from mid-stage brain cancer study seekingalpha.com May 7, 2021 10:28 pm Medicenna Therapeutics names Kevin Moulder chief scientific officer seekingalpha.com Apr 21, 2021 9:06 pm Medicenna Therapeutics reports FQ3 results seekingalpha.com Feb 12, 2021 8:16 pm Medicenna announces ATM sales facility for $25M seekingalpha.com Dec 31, 2020 7:50 pm Medicenna Therapeutics reports Q2 results seekingalpha.com Nov 13, 2020 8:20 pm Medicenna on go with pivotal trial of MDNA55 in brain cancer seekingalpha.com Oct 17, 2020 12:53 am Medicenna Therapeutics reports Q1 results seekingalpha.com Aug 4, 2020 7:45 pm Medicenna Therapeutics reports FY results seekingalpha.com May 15, 2020 7:37 pm Medicenna Therapeutics reports Q3 results seekingalpha.com Feb 13, 2020 9:09 pm Medicenna Therapeutics reports Q2 results seekingalpha.com Nov 5, 2019 9:14 pm Medicenna files for equity offering seekingalpha.com Oct 11, 2019 9:49 pm This company doesn't provide a dividend.
Talk about Medicenna Therapeutics Corp below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written.
